IVD China last week: Thermo Fisher Scientific and RealBio, Dirui and TechVital, DIAN Diagnostics, ADICON, BioChain

RealBio and Thermo Fisher Scientific Partner on IVD Quality Control Solutions

On May 12 in Shanghai, RealBio signed a strategic agreement with Thermo Fisher Scientific to collaborate on comprehensive quality control solutions for in vitro diagnostics. The partnership aims to combine Thermo Fisher’s global standards and technical depth with RealBio’s strengths in local translation, regulatory support, and IVD raw material development.

By aligning global quality systems with China’s IVD innovation and manufacturing ecosystem, the two companies seek to streamline the path from R&D to industrialization for domestic manufacturers. The collaboration signals a shift from traditional supply relationships toward a model of shared resources and value co-creation in the IVD quality infrastructure space.

Dirui Industrial Co., Ltd. Partners with TechVital to Deploy CSM-8000 in Bangladesh

Dirui has formed a strategic partnership with TechVital, a healthcare subsidiary of United Group in Bangladesh, to enhance integrated laboratory solution capabilities in the local market. As the first milestone, Dirui’s CSM-8000 Modular Clinical Chemistry & Immunoassay System has been installed at M A Rashid Hospital, with a daily testing capacity of 300–400 samples.

The system was jointly showcased at Meditex Bangladesh in May, highlighting its clinical applications and technical strengths. The collaboration marks the start of broader efforts to upgrade laboratory services and expand comprehensive solutions across Bangladesh’s healthcare sector.

DIAN Diagnostics Partners with West China Hospital Sichuan University on Non-Invasive Epilepsy Prediction

DIAN Diagnostics has partnered with Professor Chen Lei’s team at West China Hospital of Sichuan University to accelerate the clinical translation of a urine protein–based method for predicting epileptic seizures. The approach extends the warning window from roughly one hour with conventional EEG monitoring to up to 24 hours, offering a non-invasive and practical solution for long-term, home-based seizure risk management.

By combining clinical research expertise with DIAN’s capabilities in validation, industrialization, and nationwide precision medicine networks, the collaboration aims to bring this innovation from laboratory discovery to real-world application. The initiative highlights a new pathway for proactive epilepsy management, shifting care from reactive response to early risk prediction through accessible biomarker testing.

ADICON and Digital China Form Strategic Alliance for AI-Driven Smart Diagnostics

ADICON signed a three-year strategic agreement with Digital China to accelerate ecosystem-led, scenario-based deployment of AI in medical diagnostics. Leveraging ADICON’s nationwide lab network, proprietary medical AI model “Wenyi,” and large-scale pathology AI applications, the partnership will integrate Digital China’s enterprise AI and agent platform to enable compliant, scalable smart lab solutions.

The collaboration marks ADICON’s shift from internal AI efficiency tools to standardized, industry-level AI services—advancing from single-point applications to an ecosystem approach for intelligent diagnostics across clinical testing, quality control, and service delivery.

BioChain (Beijing) Science & Technology, Inc. Advances Multi-Cancer Early Detection with Methylation Entropy Model

BioChain, together with researchers from Peking University Cancer Hospital and Beijing Institute of Genomics Chinese Academy of Sciences, published a study in the Journal of Translational Medicine introducing “methylation entropy” as a novel analytical dimension for liquid biopsy. The multimodal framework demonstrated strong performance for early detection and tissue-of-origin classification across seven major cancers, achieving an AUC of 0.979 with 93.4% sensitivity and specificity, and 92.3% accuracy for origin tracing.

By integrating this new epigenetic signal into NGS-based workflows, the research highlights a scalable path toward more precise multi-cancer screening and clinical decision support, reinforcing the growing role of advanced methylation analytics in early cancer diagnostics.